IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 554-567

  Moreno, María J ^a   Ball, Marguerite ^a   Rukhlova, Marina ^a   Slinn, Jacqueline ^a   L'Abbe, Denis ^a   Iqbal, Umar ^a   Monette, Robert ^a   Hagedorn, Martin ^b,c   O'Connor McCourt, Maureen D ^a   Durocher, Yves ^a   Stanimirovic, Danica B ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 4; ANGIOGENESIS INHIBITOR; CIBP-4 PEPTIDE; CTSB PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CELL ANCHORAGE; CELL GROWTH; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE SECTION; TUMOR GROWTH; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHICK EMBRYO; DRUG EFFECTS; DRUG SCREENING; ENDOTHELIUM CELL; ENZYMOLOGY; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUDE MOUSE; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CATHEPSIN B; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; ENDOTHELIAL CELLS; GLIOBLASTOMA; HEK293 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877034486     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13212     Document Type: Article

References (64)

1. Firth SM and Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23, 824-854.
2. Baxter RC (1993). Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 4, 91-96.
3. Murphy LJ (1998). Insulin-like growth factor-binding proteins: functional diversity or redundancy? J Mol Endocrinol 21, 97-107.
4. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EE, Weiler J, et al. (1995). IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5, 1-17.
5. Fowlkes JL and Serra DM (1996). Characterization of glycosaminoglycanbinding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 271, 14676-14679.
6. Russo VC, Bach LA, Fosang AJ, Baker NL, and Werther GA (1997). Insulinlike growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 138, 4858-4867.
7. Mohan S and Baylink DJ (2002). IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175, 19-31.
8. Zhou R, Diehl D, Hoeflich A, Lahm H, and Wolf E (2003). IGF-binding protein-4: biochemical characteristics and functional consequences. J Endocrinol 178, 177-193.
9. Ceda GP, Fielder PJ, Henzel WJ, Louie A, Donovan SM, Hoffman AR, and Rosenfeld RG (1991). Differential effects of insulin-like growth factor (IGF)-I and IGF-II on the expression of IGF binding proteins (IGFBPs) in a rat neuroblastoma cell line: isolation and characterization of two forms of IGFBP-4. Endocrinology 128, 2815-2824.
10. Moreno MJ, Ball M, Andrade MF, McDermid A, and Stanimirovic DB (2006). Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)--differentiated glioblastoma cells. Glia 53, 845-857.
11. Contois LW, Nugent DP, Caron JM, Cretu A, Tweedie E, Akalu A, Liebes L, Friesel R, Rosen C, Vary C, et al. (2012). Insulin-like growth factor binding protein-4 differentially inhibits growth factor-induced angiogenesis. J Biol Chem 287, 1779-1789.
12. Novinec M, Kordis D, Turk V, and Lenarcic B (2006). Diversity and evolution of the thyroglobulin type-1 domain superfamily. Mol Biol Evol 23, 744-755.
13. Lenarcic B and Bevec T (1998). Thyropins-new structurally related proteinase inhibitors. Biol Chem 379, 105-111.
14. Turk V, Turk B, Guncar G, Turk D, and Kos J (2002). Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 42, 285-303.
15. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, and Hanahan D (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453.
16. Mai J, Sameni M, Mikkelsen T, and Sloane BF (2002). Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem 383, 1407-1413.
17. Lah TT, Buck MR, Honn KV, Crissman JD, Rao NC, Liotta LA, and Sloane BF (1989). Degradation of laminin by human tumor cathepsin B. Clin Exp Metastasis 7, 461-468.
18. Buck MR, Karustis DG, Day NA, Honn KV, and Sloane BF (1992). Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282(pt 1), 273-278.
19. Skrzydlewska E, Sulkowska M, Koda M, and Sulkowski S (2005). Proteolyticantiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 11, 1251-1266.
20. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, Fuller GN, Yung AW, Kyritsis AP, Dinh DH, et al. (2001). Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20, 3665-3673.
21. Premzl A, Turk V, and Kos J (2006). Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J Cell Biochem 97, 1230-1240.
22. Wang M, Tang J, Liu S, Yoshida D, and Teramoto A (2005). Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol 71, 3-7.
23. Strojnik T, Kos J, Zidanik B, Golouh R, and Lah T (1999). Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 5, 559-567.
24. Cass B, Pham PL, Kamen A, and Durocher Y (2005). Purification of recombinant proteins from mammalian cell culture using a generic double-affinity chromatography scheme. Protein Expr Purif 40, 77-85.
25. Shi C, Shin YO, Hanson J, Cass B, Loewen MC, and Durocher Y (2005). Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 EBNA1 cells. Biochemistry 44, 15705-15714.
26. Durocher Y, Perret S, and Kamen A (2002). High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30, E9.
27. Pham PL, Perret S, Cass B, Carpentier E, St-Laurent G, Bisson L, Kamen A, and Durocher Y (2005). Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis. Biotechnol Bioeng 90, 332-344.
28. Tom R, Bisson L, and Durocher Y (2008). Purification of His-tagged proteins using fractogel-cobalt. CSH Protoc 2008, pdb.prot4980.
29. Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, Afkhamizarreh F, and Durocher Y (2008). Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol 8, 65.
30. Stanimirovic D, Morley P, Ball R, Hamel E, Mealing G, and Durkin JP (1996). Angiotensin II-induced fluid phase endocytosis in human cerebromicrovascular endothelial cells is regulated by the inositol-phosphate signaling pathway. J Cell Physiol 169, 455-467.
31. Freitas-Andrade M, Carmeliet P, Stanimirovic DB, and Moreno M (2008). VEGFR-2-mediated increased proliferation and survival in response to oxygen and glucose deprivation in PlGF knockout astrocytes. J Neurochem107, 756-767.
32. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A, and Bikfalvi A (2005). Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 102, 1643-1648.
33. Pen A, Durocher Y, Slinn J, Rukhlova M, Charlebois C, Stanimirovic DB, and Moreno MJ (2011). Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines. Cancer Biol Ther 12, 634-646.
34. Iqbal U, Albaghdadi H, Luo Y, Arbabi M, Desvaux C, Veres T, Stanimirovic D, and Abulrob A (2010). Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br J Cancer 103, 1606-1616.
35. Rechler MM (1993). Insulin-like growth factor binding proteins. Vitam Horm 47, 1-114.
36. Clemmons DR (1998). Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140, 19-24.
37. Wetterau LA, Moore MG, Lee KW, Shim ML, and Cohen P (1999). Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 68, 161-181.
38. Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, and Sloane BF (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54, 6027-6031.
39. Lakka SS, Gondi CS, and Rao JS (2005). Proteases and glioma angiogenesis. Brain Pathol 15, 327-341.
40. Colin C, Voutsinos-Porche B, Nanni I, Fina F, Metellus P, Intagliata D, Baeza N, Bouvier C, Delfino C, Loundou A, et al. (2009). High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 118, 745-754.
41. Strojnik T, Kavalar R, Trinkaus M, and Lah TT (2005). Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev 29, 448-455.
42. Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmolzer J, Haffner MC, Klocker H, Huber LA, Geley S, et al. (2007). Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic 8, 1815-1828.
43. 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90, 10553-10557.
44. Leal SM, Liu Q, Huang SS, and Huang JS (1997). The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272, 20572-20576.
45. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, and Rosenfeld RG (1996). Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28, 619-637.
46. Im E, Venkatakrishnan A, and Kazlauskas A (2005). Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 16, 3488-3500.
47. Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, and Sloane BF (2009). Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res 315, 1234-1246.
48. Yanamandra N, Gumidyala KV, Waldron KG, Gujrati M, Olivero WC, Dinh DH, Rao JS, and Mohanam S (2004). Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23, 2224-2230.
49. Malla RR, Gopinath S, Gondi CS, Alapati K, Dinh DH, Gujrati M, and Rao JS (2011). Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther 18, 419-434.
50. Mason SD and Joyce JA (2011). Proteolytic networks in cancer. Trends Cell Biol 21, 228-237.
51. Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL, and Rao JS (1995). Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13, 49-56.
52. Demchik LL, Sameni M, Nelson K, Mikkelsen T, and Sloane BF (1999). Cathepsin B and glioma invasion. Int J Dev Neurosci 17, 483-494.
53. Konduri S, Lakka SS, Tasiou A, Yanamandra N, Gondi CS, Dinh DH, Olivero WC, Gujrati M, and Rao JS (2001). Elevated levels of cathepsin B in human glioblastoma cell lines. Int J Oncol 19, 519-524.
54. Lah TT, Strojnik T, Levicar N, Bervar A, Zajc I, Pilkington G, and Kos J (2000). Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Int J Biol Markers 15, 90-93.
55. Premzl A, Zavasnik-Bergant V, Turk V, and Kos J (2003). Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 283, 206-214.
56. Krueger S, Haeckel C, Buehling F, and Roessner A (1999). Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res 59, 6010-6014.
57. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, and Rao JS (2004). Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23, 4681-4689.
58. Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, and Rosenblum ML (1995). Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 83, 285-290.
59. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, and Emmert-Buck MR (1994). Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25, 857-862.
60. Yuan A, Chen JJ, and Yang PC (2008). Pathophysiology of tumor-associated macrophages. Adv Clin Chem 45, 199-223.
61. Eeckhout Y and Vaes G (1977). Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 166, 21-31.
62. Somanna A, Mundodi V, and Gedamu L (2002). Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor β. J Biol Chem 277, 25305-25312.
63. Kostoulas G, Lang A, Nagase H, and Baici A (1999). Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett 455, 286-290.
64. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, and Joyce JA (2007). Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 67, 7378-7385.